Safety and effectiveness of peficitinib 100 mg/day in patients achieving clinical remission from a long-term open-label extension study in Japan, Korea, and Taiwan (RAJ2).
Yoshiya TanakaTsutomu TakeuchiYoshiaki MoritaYuichiro KanekoWataru TeradaPublished in: Modern rheumatology (2024)
Long-term peficitinib treatment at a dose of 100 mg/day was generally well tolerated and, following induction therapy, maintained effectiveness through to W48.